These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24599010)

  • 1. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.
    Matsui K; Kim-Mitsuyama S; Ogawa H; Jinnouchi T; Jinnouchi H; Arakawa K;
    Hypertens Res; 2014 Jun; 37(6):526-32. PubMed ID: 24599010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study.
    Kim-Mitsuyama S; Ogawa H; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Hypertens Res; 2015 Mar; 38(3):199-207. PubMed ID: 25471234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
    J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
    Takami T; Saito Y
    Vasc Health Risk Manag; 2011; 7():383-90. PubMed ID: 21796252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
    Rafiq K; Nishiyama A; Konishi Y; Morikawa T; Kitabayashi C; Kohno M; Masaki T; Mori H; Kobori H; Imanishi M
    PLoS One; 2014; 9(9):e107853. PubMed ID: 25233358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.
    Kim-Mitsuyama S; Ogawa H; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K
    Kidney Int; 2013 Jan; 83(1):167-76. PubMed ID: 23051740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.
    Ogihara T; Saruta T; Rakugi H; Saito I; Shimamoto K; Matsuoka H; Shimada K; Ito S; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Kimura G; Umemura S; Ura N; Hayashi K; Odawara M; Tanahashi N; Ishimitsu T; Kashihara N; Morita S; Teramukai S;
    J Hypertens; 2014 Oct; 32(10):2054-63; discussiom 2063. PubMed ID: 24999799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central blood pressure under angiotensin and calcium channel blockade.
    Safar ME; Protogerou A; Blacher J
    Hypertension; 2009 Oct; 54(4):704-6. PubMed ID: 19667254
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
    Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
    J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
    Ogihara T; Saruta T; Rakugi H; Shimamoto K; Ito S; Matsuoka H; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Saito I; Shimada K;
    Hypertens Res; 2009 Feb; 32(2):163-7. PubMed ID: 19262477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study.
    Mourad JJ; Le Jeune S
    Clin Drug Investig; 2009; 29(6):419-25. PubMed ID: 19432501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.